Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25


Phosphorylation of the HCN channel auxiliary subunit TRIP8b is altered in an animal model of temporal lobe epilepsy and modulates channel function.

Foote KM, Lyman KA, Han Y, Michailidis IE, Heuermann RJ, Mandikian D, Trimmer JS, Swanson GT, Chetkovich DM.

J Biol Chem. 2019 Sep 5. pii: jbc.RA119.010027. doi: 10.1074/jbc.RA119.010027. [Epub ahead of print]


Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent.

Foote KM, Nissink JWM, McGuire T, Turner P, Guichard S, Yates JWT, Lau A, Blades K, Heathcote D, Odedra R, Wilkinson G, Wilson Z, Wood CM, Jewsbury PJ.

J Med Chem. 2018 Nov 21;61(22):9889-9907. doi: 10.1021/acs.jmedchem.8b01187. Epub 2018 Nov 10.


HCN channels in the hippocampus regulate active coping behavior.

Fisher DW, Han Y, Lyman KA, Heuermann RJ, Bean LA, Ybarra N, Foote KM, Dong H, Nicholson DA, Chetkovich DM.

J Neurochem. 2018 Sep;146(6):753-766. doi: 10.1111/jnc.14539. Epub 2018 Aug 9.


Excitatory Synaptic Input to Hilar Mossy Cells under Basal and Hyperexcitable Conditions.

Hedrick TP, Nobis WP, Foote KM, Ishii T, Chetkovich DM, Swanson GT.

eNeuro. 2017 Dec 4;4(6). pii: ENEURO.0364-17.2017. doi: 10.1523/ENEURO.0364-17.2017. eCollection 2017 Nov-Dec.


Cutaneous Vasodilation during Local Heating: Role of Local Cutaneous Thermosensation.

Mack GW, Foote KM, Nelson WB.

Front Physiol. 2016 Dec 20;7:622. doi: 10.3389/fphys.2016.00622. eCollection 2016.


Discovery of 4,6-disubstituted pyrimidines as potent inhibitors of the heat shock factor 1 (HSF1) stress pathway and CDK9.

Rye CS, Chessum NE, Lamont S, Pike KG, Faulder P, Demeritt J, Kemmitt P, Tucker J, Zani L, Cheeseman MD, Isaac R, Goodwin L, Boros J, Raynaud F, Hayes A, Henley AT, de Billy E, Lynch CJ, Sharp SY, Te Poele R, Fee LO, Foote KM, Green S, Workman P, Jones K.

Medchemcomm. 2016 Aug 1;7(8):1580-1586. Epub 2016 Jun 13.


Potent and Selective Inhibitors of MTH1 Probe Its Role in Cancer Cell Survival.

Kettle JG, Alwan H, Bista M, Breed J, Davies NL, Eckersley K, Fillery S, Foote KM, Goodwin L, Jones DR, Käck H, Lau A, Nissink JW, Read J, Scott JS, Taylor B, Walker G, Wissler L, Wylot M.

J Med Chem. 2016 Mar 24;59(6):2346-61. doi: 10.1021/acs.jmedchem.5b01760. Epub 2016 Feb 16.


Left Main Coronary Artery Occlusion and the Collateral-Dependent Heart.

Morris BN, Locke AQ, Foote KM, Royster RL.

J Cardiothorac Vasc Anesth. 2016 Jan;30(1):179-83. doi: 10.1053/j.jvca.2015.04.003. Epub 2015 Apr 9. No abstract available.


Drugging ATR: progress in the development of specific inhibitors for the treatment of cancer.

Foote KM, Lau A, Nissink JW.

Future Med Chem. 2015;7(7):873-91. doi: 10.4155/fmc.15.33. Review.


An enantiospecific polyene cyclization initiated by an enantiomerically pure bromonium ion.

Braddock DC, Marklew JS, Foote KM, White AJ.

Chirality. 2013 Nov;25(11):692-700. doi: 10.1002/chir.22194. Epub 2013 Jul 26. Erratum in: Chirality. 2014 Jul;26(7):i-ii.


Discovery of 4-{4-[(3R)-3-Methylmorpholin-4-yl]-6-[1-(methylsulfonyl)cyclopropyl]pyrimidin-2-yl}-1H-indole (AZ20): a potent and selective inhibitor of ATR protein kinase with monotherapy in vivo antitumor activity.

Foote KM, Blades K, Cronin A, Fillery S, Guichard SS, Hassall L, Hickson I, Jacq X, Jewsbury PJ, McGuire TM, Nissink JW, Odedra R, Page K, Perkins P, Suleman A, Tam K, Thommes P, Broadhurst R, Wood C.

J Med Chem. 2013 Mar 14;56(5):2125-38. doi: 10.1021/jm301859s. Epub 2013 Mar 1.


First metatarsophalangeal arthrodesis: a biomechanical comparison of three fixation constructs.

Foote KM, Teasdall RD, Tanaka ML, Scott AT.

J Surg Orthop Adv. 2012 Winter;21(4):223-31.


Protein-ligand crystal structures can guide the design of selective inhibitors of the FGFR tyrosine kinase.

Norman RA, Schott AK, Andrews DM, Breed J, Foote KM, Garner AP, Ogg D, Orme JP, Pink JH, Roberts K, Rudge DA, Thomas AP, Leach AG.

J Med Chem. 2012 Jun 14;55(11):5003-12. doi: 10.1021/jm3004043. Epub 2012 May 21.


Adaptations to high-intensity intermittent exercise in rodents.

Bexfield NA, Parcell AC, Nelson WB, Foote KM, Mack GW.

J Appl Physiol (1985). 2009 Sep;107(3):749-54. doi: 10.1152/japplphysiol.91446.2008. Epub 2009 Jul 16.


Nonselective NOS inhibition blunts the sweat response to exercise in a warm environment.

Welch G, Foote KM, Hansen C, Mack GW.

J Appl Physiol (1985). 2009 Mar;106(3):796-803. doi: 10.1152/japplphysiol.90809.2008. Epub 2009 Jan 8.


Synthesis and SAR of 1-acetanilide-4-aminopyrazole-substituted quinazolines: selective inhibitors of Aurora B kinase with potent anti-tumor activity.

Foote KM, Mortlock AA, Heron NM, Jung FH, Hill GB, Pasquet G, Brady MC, Green S, Heaton SP, Kearney S, Keen NJ, Odedra R, Wedge SR, Wilkinson RW.

Bioorg Med Chem Lett. 2008 Mar 15;18(6):1904-9. doi: 10.1016/j.bmcl.2008.02.002. Epub 2008 Feb 7.


Synthesis and structure-activity relationships of thieno[2,3-b]pyrroles as antagonists of the GnRH receptor.

Arnould JC, Delouvrié B, Boutron P, Dossetter AG, Foote KM, Hamon A, Hancox U, Harris CS, Hutton M, Lamorlette M, Matusiak Z.

Bioorg Med Chem Lett. 2007 Dec 1;17(23):6448-54. Epub 2007 Oct 4.


AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis.

Wilkinson RW, Odedra R, Heaton SP, Wedge SR, Keen NJ, Crafter C, Foster JR, Brady MC, Bigley A, Brown E, Byth KF, Barrass NC, Mundt KE, Foote KM, Heron NM, Jung FH, Mortlock AA, Boyle FT, Green S.

Clin Cancer Res. 2007 Jun 15;13(12):3682-8.


Discovery, synthesis, and in vivo activity of a new class of pyrazoloquinazolines as selective inhibitors of aurora B kinase.

Mortlock AA, Foote KM, Heron NM, Jung FH, Pasquet G, Lohmann JJ, Warin N, Renaud F, De Savi C, Roberts NJ, Johnson T, Dousson CB, Hill GB, Perkins D, Hatter G, Wilkinson RW, Wedge SR, Heaton SP, Odedra R, Keen NJ, Crafter C, Brown E, Thompson K, Brightwell S, Khatri L, Brady MC, Kearney S, McKillop D, Rhead S, Parry T, Green S.

J Med Chem. 2007 May 3;50(9):2213-24. Epub 2007 Mar 21.


Validating Aurora B as an anti-cancer drug target.

Girdler F, Gascoigne KE, Eyers PA, Hartmuth S, Crafter C, Foote KM, Keen NJ, Taylor SS.

J Cell Sci. 2006 Sep 1;119(Pt 17):3664-75. Epub 2006 Aug 15.


Progress in the development of selective inhibitors of aurora kinases.

Mortlock AA, Keen NJ, Jung FH, Heron NM, Foote KM, Wilkinson RW, Green S.

Curr Top Med Chem. 2005;5(8):807-21. Review.


Progress in the development of selective inhibitors of Aurora kinases.

Mortlock A, Keen NJ, Jung FH, Heron NM, Foote KM, Wilkinson R, Green S.

Curr Top Med Chem. 2005;5(2):199-213. Review. Erratum in: Curr Top Med Chem. 2005;5(8):805. Corrected and republished in: Curr Top Med Chem. 2005;5(8):807-21.


Selective antagonism of the NPY Y5 receptor does not have a major effect on feeding in rats.

Turnbull AV, Ellershaw L, Masters DJ, Birtles S, Boyer S, Carroll D, Clarkson P, Loxham SJ, McAulay P, Teague JL, Foote KM, Pease JE, Block MH.

Diabetes. 2002 Aug;51(8):2441-9.


Discovery and optimization of a series of carbazole ureas as NPY5 antagonists for the treatment of obesity.

Block MH, Boyer S, Brailsford W, Brittain DR, Carroll D, Chapman S, Clarke DS, Donald CS, Foote KM, Godfrey L, Ladner A, Marsham PR, Masters DJ, Mee CD, O'Donovan MR, Pease JE, Pickup AG, Rayner JW, Roberts A, Schofield P, Suleman A, Turnbull AV.

J Med Chem. 2002 Aug 1;45(16):3509-23.


Supplemental Content

Loading ...
Support Center